| 1 |
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian David Lehmann, Joshua A. Bauer, Xi Chen et al. · Journal of Clinical Investigation
Open access |
10 Jun 2011 |
5,662 |
| 2 |
Breast Cancer Treatment
Adrienne Gropper Waks, Eric P. Winer · JAMA
|
22 Jan 2019 |
5,015 |
| 3 |
Circulating Tumor Cells, Disease Progression, and Survival in Metastatic Breast Cancer
Massimo Cristofanilli, George Thomas Budd, Matthew J. Ellis et al. · New England Journal of Medicine
Open access |
18 Aug 2004 |
4,641 |
| 4 |
Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer
Peter Schmid, Sylvia Adams, Hope S. Rugo et al. · New England Journal of Medicine
Open access |
20 Oct 2018 |
4,469 |
| 5 |
Triple-Negative Breast Cancer
William David Foulkes, Ian E. Smith, Jorge Sergio Reis-Filho · New England Journal of Medicine
|
10 Nov 2010 |
4,277 |
| 6 |
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
Aron Goldhirsch et al. · Annals of Oncology
Open access |
6 Aug 2013 |
3,776 |
| 7 |
Lapatinib plus Capecitabine for HER2-Positive Advanced Breast Cancer
Charles E. Geyer, John Forster, Deborah L. Lindquist et al. · New England Journal of Medicine
Open access |
27 Dec 2006 |
3,486 |
| 8 |
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Mark E. Robson, Seock‐Ah Im, Elżbieta Senkus et al. · New England Journal of Medicine
Open access |
4 Jun 2017 |
3,322 |
| 9 |
Palbociclib and Letrozole in Advanced Breast Cancer
Richard S. Finn, Miguel Martín, Hope S. Rugo et al. · New England Journal of Medicine
|
16 Nov 2016 |
3,059 |
| 10 |
Breast cancer
Nadia Harbeck, Frederique Madeleine Penault-Llorca, Javier Cortés et al. · Nature Reviews Disease Primers
ReviewOpen access |
23 Sep 2019 |
3,056 |
| 11 |
Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast Cancer
Charles L. Vogel · Journal of Clinical Oncology
|
Feb 2002 |
2,953 |
| 12 |
Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
Kathleen N. Moore et al. · New England Journal of Medicine
Open access |
21 Oct 2018 |
2,927 |
| 13 |
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
José Baselga et al. · New England Journal of Medicine
Open access |
7 Dec 2011 |
2,868 |
| 14 |
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
Fabrice André, Eva M. Ciruelos, Gábor Rubovszky et al. · New England Journal of Medicine
Open access |
15 May 2019 |
2,660 |
| 15 |
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin, Jiang-Jie Duan, Xiu-Wu Bian et al. · Breast Cancer Research
Open access |
9 Jun 2020 |
2,604 |
| 16 |
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor R. Mirza et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,495 |
| 17 |
Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer
Joseph A. Sparano et al. · New England Journal of Medicine
Open access |
3 Jun 2018 |
2,447 |
| 18 |
Breast cancer
Nadia Harbeck, Michael Gnant · The Lancet
|
16 Nov 2016 |
2,347 |
| 19 |
Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer
Anthony Howell, Jack M. Cuzick, Michael Baum et al. · The Lancet
|
2005 |
2,295 |
| 20 |
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Fátima Cardoso, Stella Kyriakides, Shinji Ohno et al. · Annals of Oncology
Open access |
22 May 2019 |
2,287 |
| 21 |
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer Keating Litton, Hope S. Rugo, Johannes Ettl et al. · New England Journal of Medicine
Open access |
15 Aug 2018 |
2,198 |
| 22 |
Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer
Sandra M. Swain, José Baselga, Sung‐Bae Kim et al. · New England Journal of Medicine
Open access |
18 Feb 2015 |
2,183 |
| 23 |
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Tony R. Hunter, Jonathon Pines · Cell
|
Nov 1994 |
2,119 |
| 24 |
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
Antonino Glaviano et al. · Molecular Cancer
Open access |
18 Aug 2023 |
2,108 |
| 25 |
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
Fátima Cardoso et al. · Annals of Oncology
Open access |
11 Oct 2016 |
2,075 |
| 26 |
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
Gabriel N. Hortobágyi et al. · New England Journal of Medicine
Open access |
8 Oct 2016 |
2,066 |
| 27 |
Risk Factors and Preventions of Breast Cancer
Yi-Sheng Sun, Zhao Zhao, Zhang-Nv Yang et al. · International Journal of Biological Sciences
Open access |
2017 |
2,053 |
| 28 |
Breast Cancer—Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies—An Updated Review
Sergiusz Łukasiewicz, Marcin Czeczelewski, Alicja Forma et al. · Cancers
Open access |
25 Aug 2021 |
1,968 |
| 29 |
Cell cycle proteins as promising targets in cancer therapy
Tobias Otto, Piotr Siciński · Nature reviews. Cancer
ReviewOpen access |
27 Jan 2017 |
1,945 |
| 30 |
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn, John P. Crown, István Láng et al. · The Lancet Oncology
|
15 Dec 2014 |
1,934 |
| 31 |
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan A. Ledermann, Philipp Harter, Charlie Gourley et al. · New England Journal of Medicine
|
27 Mar 2012 |
1,916 |
| 32 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
Éric Pujade-Lauraine et al. · The Lancet Oncology
Open access121 authors |
25 Jul 2017 |
1,891 |
| 33 |
20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years
Hongchao Pan, Richard G. Gray, Jeremy P. Braybrooke et al. · New England Journal of Medicine
Open access |
8 Nov 2017 |
1,883 |
| 34 |
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Massimo Cristofanilli, Nicholas C. Turner, Igor Bondarenko et al. · The Lancet Oncology
Open access |
2 Mar 2016 |
1,870 |
| 35 |
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
Alan Stuart Coates et al. · Annals of Oncology
Open access |
4 May 2015 |
1,865 |
| 36 |
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
Javier Cortés et al. · The Lancet
Open access227 authors |
Dec 2020 |
1,856 |
| 37 |
A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer
Paul Edward Goss, James N. Ingle, Silvana Martino et al. · New England Journal of Medicine
Open access |
6 Nov 2003 |
1,833 |
| 38 |
Cancer chemotherapy and beyond: Current status, drug candidates, associated risks and progress in targeted therapeutics
Uttpal Anand, Abhijit Dey, Arvind K. Singh Chandel et al. · Genes & Diseases
Open access |
18 Mar 2022 |
1,808 |
| 39 |
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Saddia Asghar, Agnieszka Katarzyna Witkiewicz, Nicholas C. Turner et al. · Nature Reviews Drug Discovery
ReviewOpen access |
30 Jan 2015 |
1,805 |
| 40 |
Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction
Ji Luo, Nicole L. Solimini, Stephen J. Elledge · Cell
Open access |
Mar 2009 |
1,790 |
| 41 |
MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
Matthew Philip Goetz, Masakazu Toi, Mario Campone et al. · Journal of Clinical Oncology
Open access |
2 Oct 2017 |
1,770 |
| 42 |
Adjuvant Olaparib for Patients with BRCA1 - or BRCA2 -Mutated Breast Cancer
Andrew N.J. Tutt et al. · New England Journal of Medicine
Open access |
3 Jun 2021 |
1,744 |
| 43 |
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
Robert Louis Coleman et al. · The Lancet
Open access117 authors |
12 Sep 2017 |
1,729 |
| 44 |
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
George W. Sledge, Masakazu Toi, Patrick Neven et al. · Journal of Clinical Oncology
Open access |
3 Jun 2017 |
1,710 |
| 45 |
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Lei Zhong, Yueshan Li, Liang Xiong et al. · Signal Transduction and Targeted Therapy
Open access |
30 May 2021 |
1,707 |
| 46 |
Breast cancer
Sibylle Loibl, Philip M. Poortmans, Monica Morrow et al. · The Lancet
|
2 Apr 2021 |
1,696 |
| 47 |
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer
Aditya Bardia et al. · New England Journal of Medicine
Open access |
21 Apr 2021 |
1,671 |
| 48 |
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Elżbieta Senkus, Stella Kyriakides, Shinji Ohno et al. · Annals of Oncology
Open access |
27 Aug 2015 |
1,660 |
| 49 |
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
Andrew N.J. Tutt, Mark E. Robson, Judy Ellen Garber et al. · The Lancet
|
Jul 2010 |
1,660 |
| 50 |
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology
William John Gradishar et al. · Journal of the National Comprehensive Cancer Network
|
Apr 2020 |
1,628 |